Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.

The treatment effect did not reach statistical significance for the primary or two key secondary endpoints, and showed no clinical benefit of abatacept over placebo in other clinical efficacy and patient-reported outcome endpoints at the end of the double-blind period at day 169, or at the end of the open-label extended follow-up period at day 365.

also in 111,027 other papers